학술논문
替米沙坦联合苯磺酸左旋氨氯地平治疗原发性高血压患者的效果 / Effects of Telmisartan combined with Levamlodipine besylate in treatment of patients with essential hypertension
Document Type
Academic Journal
Author
孙孟华; 马佳琪; 侯永茂; 刘军利; 罗进光; 闫航; 任志杰; SUN Menghua; MA Jiaqi; HOU Yongmao; LIU Junli; LUO Jinguang; YAN Hang; REN Zhijie
Source
中国民康医学 / Medical Journal of Chinese People's Health. 35(22):40-42
Subject
Language
Chinese
ISSN
1672-0369
Abstract
目的:观察替米沙坦联合苯磺酸左旋氨氯地平治疗原发性高血压患者的效果.方法:选取 2021-2022 年该院收治的120例原发性高血压患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各60例.对照组予以苯磺酸左氨氯地平治疗,观察组在对照组基础上联合替米沙坦治疗,两组均持续治疗 4 个月.比较两组治疗前后血压水平、临床疗效、肾功能指标[血肌酐(Scr)、血尿素氮(BUN)、尿白蛋白排泄率(UAER)]水平,以及不良反应发生率.结果:治疗后,观察组收缩压、舒张压水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率为 93.33%(56/60),高于对照组的 80.00%(48/60),差异有统计学意义(P<0.05);治疗后,观察组Scr、UAER、BUN水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:替米沙坦联合苯磺酸左旋氨氯地平治疗原发性高血压患者可提高治疗总有效率,降低血压水平和肾功能指标水平,效果优于单纯苯磺酸左旋氨氯地平治疗.
Objective:To observe effects of Telmisartan combined with Levamlodipine besylate in treatment of patients with essential hypertension.Methods:A prospective study was conducted on 120 patients with essential hypertension admitted to this hospital from 2021 to 2022.They were divided into control group and observation group according to the random number table method,60 cases in each group.The control group was treated with Levamlodipine besylate,while the observation group was treated with Telmisartan on the basis of the control group.Both groups were treated for 4 months.The blood pressure levels,the clinical efficacy,the renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN),urinary albumin excretion rate(UAER)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of systolic blood pressure and diastolic blood pressure in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 93.33%(56/60),which was higher than 80.00%(48/60)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of Scr,UAER and BUN in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Telmisartan combined with Levamlodipine besylate in the treatment of the patients with essential hypertension can improve the total effective rate of treatment and reduce the blood pressure levels and the renal function index levels.Moreover,it is superior to single Levamlodipine besylate treatment.
Objective:To observe effects of Telmisartan combined with Levamlodipine besylate in treatment of patients with essential hypertension.Methods:A prospective study was conducted on 120 patients with essential hypertension admitted to this hospital from 2021 to 2022.They were divided into control group and observation group according to the random number table method,60 cases in each group.The control group was treated with Levamlodipine besylate,while the observation group was treated with Telmisartan on the basis of the control group.Both groups were treated for 4 months.The blood pressure levels,the clinical efficacy,the renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN),urinary albumin excretion rate(UAER)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of systolic blood pressure and diastolic blood pressure in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 93.33%(56/60),which was higher than 80.00%(48/60)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of Scr,UAER and BUN in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Telmisartan combined with Levamlodipine besylate in the treatment of the patients with essential hypertension can improve the total effective rate of treatment and reduce the blood pressure levels and the renal function index levels.Moreover,it is superior to single Levamlodipine besylate treatment.